Dr Ferdinandos Skoulidis speaks to ecancer about the CodeBreaK100 trial. It evaluated the efficacy of sotorasib in pretreated KRAS p.G12C mNSCLC.
Initially, he explains the background of the study. He then talks about the methodology and key results.
Dr Skoulidis mentions that in the exploratory analyses of the phase 2 CodeBreaK 100 trial, the clinical benefit of sotorasib was observed across patient subgroups. He says that overall survival and updated exploratory analyses will be presented in the future.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.